Prognostic factors for complete response to ibrutinib in patients with chronic lymphocytic leukemia: A pooled analysis of 2 clinical trials Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Fluorodeoxyglucose F18
  • Hodgkin Disease
  • Lymphoma, Large B-Cell, Diffuse
  • Radiopharmaceuticals

abstract

  • clinicaltrials.gov Identifiers: NCT01105247 and NCT01578707.

publication date

  • May 2018

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5885180

PubMed ID

  • 29470582

Additional Document Info

start page

  • 712

end page

  • 716

volume

  • 4

number

  • 5